COMBINATION OF LOW DOSE IL-2 AND AN INHIBITOR OF TREG IL-2R DESENSITIZATION TO TREAT AUTOIMMUNE AND ALLERGIC INFLAMMATORY DISEASES
申请人:The Board of Trustees of the Leland Stanford Junior University
公开号:US20210379155A1
公开(公告)日:2021-12-09
Provided herein are methods and compositions for treating inflammatory disease by the administration, to a patient in need thereof, of an inhibitor of IL-2R desensitization in combination with a low dose of IL-2. A low dose of interleukin-2 (IL-2) is sufficient to stimulate regulatory T lymphocytes (Tregs) without substantially inducing effector T lymphocytes (Teffs). In some embodiments, the inhibitor of IL-2R desensitization is a small molecule or drug. Is some embodiments the inhibitor is a NEDD8 activating enzyme (NAE) inhibitor. In some embodiments a combination therapy provides for a synergistic effect, where the combination of the inhibitor of IL-2R desensitization and low dose IL-2 provides an effect that is greater than the sum of either the inhibitor or low dose IL-2 administered as a single agent.